235,211 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 235,211 shares of the company’s stock, valued at approximately $78,144,000. Raymond James Financial Inc. owned about 0.76% of Medpace at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. R Squared Ltd bought a new stake in shares of Medpace during the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. bought a new stake in Medpace in the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC bought a new stake in Medpace in the third quarter valued at approximately $33,000. Ashton Thomas Securities LLC bought a new stake in Medpace in the third quarter valued at approximately $37,000. Finally, Jones Financial Companies Lllp increased its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $381.44.

Medpace Stock Up 2.2 %

Shares of MEDP stock opened at $332.81 on Monday. The firm has a fifty day moving average of $341.10 and a 200-day moving average of $342.93. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a market capitalization of $10.14 billion, a price-to-earnings ratio of 26.35, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.